This recognition is a testament to Imexpharm’s unwavering commitment to sustainable development, tightly linked to community responsibility, environmental protection, and transparent governance.

For nearly five decades, Imexpharm has remained steadfast in its commitment to “Connecting Science – For Community Health,” with sustainable development as its core strategy. By embedding ESG (Environmental, Social, and Governance) principles at the heart of its operations, the company consistently delivers high-quality healthcare solutions that meet stringent EU-GMP standards. Through this approach, Imexpharm not only generates lasting value for communities and stakeholders but also plays a pivotal role in elevating Vietnam’s pharmaceutical industry on the global stage.

Tran Thi Dao, General Director of Imexpharm, shared: “In the face of rapid socioeconomic changes, Imexpharm remains committed to sustainable development under the vision: ‘A comprehensive healthcare ecosystem – For a healthier future community.’ This is the driving force that inspires us to continuously innovate, optimize operations, expand internationally, strengthen the supply chain, and stand side-by-side with the community on the journey to holistic well-being.”

To realize the vision of becoming a leading provider of high-tech pharmaceuticals in Vietnam and the region, Imexpharm has consistently invested in its EU-GMP-standard production system, with 12 advanced production lines, while enhancing its R&D capabilities. The company reinvests up to 5% of annual revenue into R&D. In 2024 alone, Imexpharm launched 24 new products, focusing on next-generation antibiotics and injectable formulations. Currently, the company holds 28 EU-MAs for 11 products authorized in the European Union - a testament to its international quality standards and global ambition.

All of Imexpharm’s manufacturing clusters, including three certified to EU-GMP standards, operate under a closed-loop system, ensuring rigorous quality control from raw material input to finished product. The company prioritizes clean, internationally certified raw materials (CEP) and employs enzymatic technology in the production of antibiotic ingredients to reduce reliance on chemical solvents, reinforcing its commitment to safety, sustainability, and global best practices.

At the same time, Imexpharm practices sustainable waste management through a strategic partnership with INSEE Ecocycle, a member of the Siam City Cement Group, offering modern co-processing solutions. Imexpharm’s green factory clusters are equipped with ISO 14001:2015-certified water systems, CIP (Cleaning In Place) and SIP (Sterilization In Place) technologies for absolute hygiene and sterilization, and advanced HVAC (Heating, Ventilation, and Air Conditioning) systems for precise temperature, humidity, and airflow control. Notably, Imexpharm is scaling up green manufacturing by deploying solar power systems, already operational at its headquarters and being expanded to major plants.

Beyond manufacturing, Imexpharm is expanding its product portfolio into specialized treatment areas such as cardiology, diabetes, neurology, and gastroenterology, with a focus on high-tech, knowledge-intensive medicines. All these efforts are driven by a clear mission: to address the healthcare needs of the community by making medicines more accessible, effective, and affordable - especially in the face of emerging and increasingly complex health challenges.

For Imexpharm, sustainable development also means walking alongside the community. In 2024, the company implemented numerous scholarship and education sponsorship programs worth VND 755 million. Imexpharm also organized free medicine distribution programs and environmental initiatives such as tree planting and waste collection. Early this year, Imexpharm donated 500 trees to the Da Lat Youth Union, contributing to the city’s plan to plant 3.8 million trees.

In addition to good manufacturing practices, environmental solutions, and social contributions, Imexpharm has also made strategic investments in governance – a cornerstone of sustainable development. The company takes pride in being listed on the VNSI20 Sustainable Development Index and in leading the way in Vietnam by adopting International Financial Reporting Standards (IFRS) and implementing the SAP S/4HANA Cloud ERP system — key steps toward enhancing transparency and aligning with the expectations of global investors and partners.

These efforts have laid a strong foundation for Imexpharm’s sustainable financial growth. In 2024, the company achieved a gross revenue of VND 2,513 billion, up 18.9% year-on-year. In the first five months of 2025, net revenue reached VND 1,001 billion, a 25% increase, with EBITDA hitting VND 211 billion, up 23% compared to the same period last year.

“We believe that a truly sustainable model is one that not only creates economic value but also spreads inspiration and leaves a lasting, positive impact on society – true to the philosophy that Imexpharm has always pursued: ‘1,000 years later, the lotus still blooms’, the general director said.